Does Rallies show 13F holders for IMUX?

Yes. Rallies tracks hedge fund and 13F ownership data for IMUX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IMUX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMUX. It does not provide personalized investment advice.

IMUX (Immunic, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Immunic, Inc. Common Stock (IMUX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMUX trades at $11.55 with a market cap of $158.83M and a P/E ratio of -17.70. IMUX moved -0.43% today. Year to date, IMUX is +81.26%; over the trailing twelve months it is +18.63%. Its 52-week range spans $5.06 to $17.30. Analyst consensus is strong buy with an average price target of $38.40. Rallies surfaces IMUX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IMUX stock?

Hedge funds tracked by Rallies that own IMUX include Renaissance Technologies, Two Sigma, Two Sigma, Two Sigma, and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunic, Inc. Common Stock.

IMUX Key Metrics

Key financial metrics for IMUX
Metric	Value
Price	$11.55
Market Cap	$158.83M
P/E Ratio	-17.70
EPS	$-0.62
Dividend Yield	0.00%
52-Week High	$17.30
52-Week Low	$5.06
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-97.17M
Gross Margin	0.00%

Top Hedge Funds Holding IMUX

Renaissance Technologies holds 566.62K shares of IMUX, changed +45.63% as of Dec 31, 2024.
Two Sigma holds 157.20K shares of IMUX, changed -40.20% as of Dec 31, 2024.
Two Sigma holds 19.88K shares of IMUX, changed +16.23% as of Sep 30, 2024.
Two Sigma holds 10.72K shares of IMUX, changed -79.28% as of Dec 31, 2024.
Citadel Advisors holds 300 shares of IMUX, changed -99.88% as of Dec 31, 2024.

Latest IMUX News

Immunic Raises $200M, Appoints New CMO and Eyes MS Phase 3 Data — May 13, 2026
Immunic Names Veteran Neurologist Michael Panzara as CMO Before Phase 3 ENSURE Readout — Apr 28, 2026
Immunic Executes 1-for-10 Reverse Split, Boosts Share Price to $9.76 — Apr 27, 2026
Immunic Restores Nasdaq Listing by Meeting $1.00 Bid Price for 20 Days — Apr 1, 2026
Immunic secures European patent extending MS drug exclusivity to 2038 — Mar 10, 2026

Recent IMUX Insider Trades

Nash Duane bought 20.00K (~$16.69K) on Jun 13, 2025.
Tardio Jason bought 12.51K (~$9.88K) on Jun 5, 2025.
Tardio Jason bought 12.51K (~$9.88K) on Jun 5, 2025.

IMUX Analyst Consensus

7 analysts cover IMUX: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.40.

Common questions about IMUX

Who owns IMUX stock?: Hedge funds tracked by Rallies that own IMUX include Renaissance Technologies, Two Sigma, Two Sigma, Two Sigma, and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunic, Inc. Common Stock.
Does Rallies show 13F holders for IMUX?: Yes. Rallies tracks hedge fund and 13F ownership data for IMUX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IMUX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMUX. It does not provide personalized investment advice.